biote Corp. (BTMD) Q3 2026 Earnings Call Transcript

Biote's Q3 2026 revenue fell 9.6% year over year to $43.3 million, while net income dropped to $0.6 million from $9.2 million and adjusted EBITDA declined to $5.1 million from $12.9 million. Procedure revenue fell 15.1% to $28.9 million, and gross margin contracted to 67.7% from 71.8%, though it improved 31 basis points sequentially as internal pellet production recovered after the January recall. Management said the return to growth is slower than anticipated but maintained FY2026 guidance of revenue above $175 million and adjusted EBITDA above $25 million. Asteria is expected to supply over 50% of shipped pellets in the current quarter, up from 30% in Q2.

Analysis

The key issue is whether clinic economics recover before the commercial reset consumes more cash—not simply whether pellet production returns in-house. Asteria’s ramp can improve gross margin, but it cannot repair procedure revenue if practitioner attrition and new-clinic productivity remain weak. The 50-person sales-force expansion is therefore a near-term cost-before-benefit bet: if field activity converts slowly, operating leverage deteriorates even as manufacturing normalizes. Supplement e-commerce is a useful hedge, but its current scale is unlikely to offset prolonged procedure weakness without materially faster growth.

Near term, guidance maintenance offers limited reassurance because management itself says recovery is slower than expected. Over the next one to three quarters, watch procedure trends alongside clinic retention and new-clinic activation; margin improvement alone could mask a still-shrinking core. The cash balance and continued debt repayment narrow the margin for execution error, although positive quarterly operating cash flow argues against assuming an immediate financing event. Verify debt terms, cash-flow seasonality, and fourth-quarter guidance headroom in filings.

Contrarian case: recall-related disruption and outsourced pellets may represent a temporary trough, with internal supply restoring margin and stronger sales execution rebuilding clinics over time. But that thesis requires evidence of sustained procedure growth, not management’s early-stabilization language. A reversal in clinic attrition and improving procedure revenue would invalidate the cautious stance; renewed declines, weak conversion of sales-force activity, or cash deterioration would strengthen it.

Key Decisions for Investors

• Keep BTMD underweight / avoid initiating a long at the open; the recovery case is not yet supported by sustained procedure growth, and valuation and borrow data are unavailable for a calibrated short.
• Treat Asteria’s production recovery as a margin catalyst, not proof of demand recovery. Reassess after the next quarter using procedure revenue, clinic retention/new-clinic productivity, and gross margin together.
• Consider a tactical short only if procedure trends or cash conversion worsen and borrow/liquidity are acceptable; avoid adding solely on the reported earnings decline, since normalization of internal supply could support a sharp margin rebound.
• Falsification trigger: sustained sequential procedure growth and improving retention alongside gross-margin expansion would justify covering any short and revisiting the long thesis. Track cash, debt repayments, and sales-force productivity for downside risk.